Slingshot members are tracking this event:

Moderna (MRNA) Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data Cohorts of younger adults (n=300) and older adults (n=300) in Phase 2 study fully enrolledCohorts of older adults (ages 56-70, n=30) and elderly adults (ages 71 and above, n=30) in NIH-led Phase 1 study completed enrollment; results expected to be published once availablePivotal Phase 3 study expected to begin in July; manufacture of vaccine required to start Phase 3 study completed
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 08, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Mrna, Coronavirus Vaccine, Covid-19